A phase 2 clinical trial of ILYX-002 in immune-driven dry eye disease (DED)
Latest Information Update: 28 Mar 2025
At a glance
- Drugs ILYX 002 (Primary)
- Indications Dry eyes
- Focus Adverse reactions; First in man; Therapeutic Use
- 28 Mar 2025 New trial record
- 12 Mar 2025 According to the Iolyx Therapeutics Media Release, company announced acceptance of abstracts where the company will present new developments and updates on its lead candidate, ILYX-002 from this study, in four upcoming industry events, in Sonoma Eye Meeting, Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, British Contact Lens Association (BCLA) Clinical Conference, and 18th Annual International Ocular and Inflammation Society (IOIS) Meeting.